Tisotumab vedotin治疗经治复发或转移性宫颈癌的疗效与安全性:innovaTV 204/GOG-3023/ENGOT-cx6多中心开放标签单臂2期研究
该多中心开放标签单臂2期研究纳入102例经治复发或转移性宫颈癌患者,评估tisotumab vedotin(组织因子靶向抗体药物偶联物)的疗效与安全性。确认的客观缓解率为24%(95%CI 16-33),常见治疗相关不良事件包括脱发、鼻出血、恶心、结膜炎、疲劳和干眼。结论认为该药显示出临床意义且持久的抗肿瘤活性,安全性可控可耐受。
要点
- 经治复发或转移性宫颈癌患者中,tisotumab vedotin确认的客观缓解率为24%。
- 最常见治疗相关不良事件为脱发(38%)、鼻出血(30%)和恶心(27%)。
- 3级及以上治疗相关不良事件发生率为28%,安全性总体可控。
核心结论
- Tisotumab vedotin在经治复发或转移性宫颈癌患者中显示出临床意义且持久的抗肿瘤活性,安全性可控可耐受。
研究设计与样本
- 多中心、开放标签、单臂2期研究,在欧洲和美国35个学术中心、医院和社区诊所开展。
- 纳入102例18岁及以上复发或转移性鳞癌、腺癌或腺鳞癌宫颈癌患者,既往接受过含贝伐珠单抗双药化疗后进展,且复发/转移阶段既往系统治疗方案不超过2线。
- 主要终点为独立审查委员会基于RECIST 1.1评估的确认客观缓解率。
主要发现
- 确认的客观缓解率为24%(95%CI 16-33),其中完全缓解7例(7%),部分缓解17例(17%)。
- 最常见治疗相关不良事件包括脱发38例(38%)、鼻出血30例(30%)、恶心27例(27%)、结膜炎26例(26%)、疲劳26例(26%)和干眼23例(23%)。
- 3级及以上治疗相关不良事件28例(28%),包括中性粒细胞减少3例(3%)、疲劳2例(2%)、溃疡性角膜炎2例(2%)和周围神经病2例(2%)。
- 治疗相关严重不良事件13例(13%),最常见为周围感觉运动神经病2例(2%)和发热2例(2%);1例脓毒性休克死亡被研究者认为与治疗相关。
临床怎么用
- 对于经治复发或转移性宫颈癌患者,tisotumab vedotin可作为潜在的新治疗选择。
- 用药期间需关注脱发、鼻出血、恶心、结膜炎、疲劳和干眼等治疗相关不良事件。
- 需监测3级及以上不良事件,包括中性粒细胞减少、疲劳、溃疡性角膜炎和周围神经病。
局限性
- 本研究为单臂设计,未设对照组。
- 样本量有限,共纳入102例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few effective second-line treatments exist for women with recurrent or metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody-drug conjugate, in this patient population. METHODS: This multicentre, open-label, single-arm, phase 2 study was done across 35 academic centres, hospitals, and community practices in Europe and the USA. The study included patients aged 18 years or older who had recurrent or metastatic squamous cell, adenocarcinoma, or adenosquamous cervical cancer; disease progression on or after doublet chemotherapy with bevacizumab (if eligible by local standards); who had received two or fewer previous systemic regimens for recurrent or metastatic disease; had measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1); and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received 2·0 mg/kg (up to a maximum of 200 mg) tisotumab vedotin intravenously once every 3 weeks until disease progression (determined by the independent review committee) or unacceptable toxicity. The primary endpoint was confirmed objective response rate based on RECIST (version 1.1), as assessed by the independent review committee. Activity and safety analyses were done in patients who received at least one dose of the drug. This study is ongoing with recruitment completed and is registered with ClinicalTrials.gov, NCT03438396. FINDINGS: 102 patients were enrolled between June 12, 2018, and April 11, 2019; 101 patients received at least one dose of tisotumab vedotin. Median follow-up at the time of analysis was 10·0 months (IQR 6·1-13·0). The confirmed objective response rate was 24% (95% CI 16-33), with seven (7%) complete responses and 17 (17%) partial responses. The most common treatment-related adverse events included alopecia (38 [38%] of 101 patients), epistaxis (30 [30%]), nausea (27 [27%]), conjunctivitis (26 [26%]), fatigue (26 [26%]), and dry eye (23 [23%]). Grade 3 or worse treatment-related adverse events were reported in 28 (28%) patients and included neutropenia (three [3%] patients), fatigue (two [2%]), ulcerative keratitis (two [2%]), and peripheral neuropathies (two [2%] each with sensory, motor, sensorimotor, and neuropathy peripheral). Serious treatment-related adverse events occurred in 13 (13%) patients, the most common of which included peripheral sensorimotor neuropathy (two [2%] patients) and pyrexia (two [2%]). One death due to septic shock was considered by the investigator to be related to therapy. Three deaths unrelated to treatment were reported, including one case of ileus and two unknown causes. INTERPRETATION: Tisotumab vedotin showed clinically meaningful and durable antitumour activity with a manageable and tolerable safety profile in women with previously treated recurrent or metastatic cervical cancer. Given the poor prognosis for this patient population and the low activity of current therapies in this setting, tisotumab vedotin, if approved, would represent a new treatment for women with recurrent or metastatic cervical cancer. FUNDING: Genmab, Seagen, Gynaecologic Oncology Group, and European Network of Gynaecological Oncological Trial Groups.
引用
- Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021. PMID: 33845034. doi:10.1016/S1470-2045(21)00056-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。